Shopping Cart
Remove All
Your shopping cart is currently empty
Inebilizumab (Synonyms: VIB-0551, MT-0551, MEDI 551, 16C4-aFuc)
Catalog No. T76713 Copy Product Info
🥰Excellent
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.
Inebilizumab
Copy Product Info🥰Excellent
Catalog No. T76713
Synonyms VIB-0551, MT-0551, MEDI 551, 16C4-aFuc
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.
Inebilizumab
Cas No. 1299440-37-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $157 | In Stock | In Stock | |
| 5 mg | $397 | In Stock | In Stock | |
| 10 mg | $659 | - | In Stock | |
| 25 mg | $987 | - | In Stock | |
| 50 mg | $1,360 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.1% (SDS-PAGE); 96.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis. |
| In vitro | Derived from the mouse anti-human mAb HB12b, Inebilizumab had already shown impressive activity in depleting B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1]. Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1]. Inebilizumab demonstrates equal or better activity than Rituximab in depleting human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1]. |
| In vivo | In vivo, Inebilizumab (MEDI-551) (i.v.; once; 0-10 mg/kg) depletes B cells from blood and spleen by mouse macrophages, and it induces phagocytosis of murine B cells ex vivo[2]. |
| Synonyms | VIB-0551, MT-0551, MEDI 551, 16C4-aFuc |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD19 |
| Molecular Weight | 146.60 kDa |
| Cas No. | 1299440-37-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Inebilizumab | purchase Inebilizumab | Inebilizumab cost | order Inebilizumab | Inebilizumab in vivo | Inebilizumab in vitro | Inebilizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.